Practical Considerations, Patient Counseling, and the Need for Predictive Biomarkers

This segment focuses on real-world administration strategies, shared decision-making, and the critical unmet need for predictive biomarkers in HCC. Dr. Braiteh begins by clarifying that the high-dose dual checkpoint regimen (3 mg/kg ipilimumab + 1 mg/kg nivolumab) is only given for the first 4 cycles (approximately the first 3 months). After this induction, nivolumab can now be administered subcutaneously every 4 weeks, which provides practical advantages, such as avoiding central line placement in patients with thrombocytopenia or coagulopathy, reducing procedural risks and patient burden.

He emphasizes evaluating whether the benefits of the dual checkpoint approach (improved objective response rates, progression-free survival, and overall survival) justify potential adverse events compared with single-agent TKIs or other regimens. Dr. Akçe notes that this balance is highly individualized: patient comorbidities, robustness, support systems, access to care, and engagement in monitoring adverse events all influence suitability. Early recognition of immune-related adverse events and a multidisciplinary team approach are key to mitigating risks.

Both faculty highlight the role of shared decision-making. Patients often come informed from research or peer networks, comparing regimens such as STRIDE versus 9DW induction. Clinicians explain the differences in dosing strategies and mechanisms of action, but not necessarily in outcomes, acknowledging that cross-trial comparisons are inherently limited. Ultimately, the decision is collaborative, tailored to patient preferences, clinical context, and logistical considerations.

Finally, Dr. Akçe and Dr. Braiteh discuss the lack of predictive biomarkers in HCC as a major limitation in personalizing frontline therapy. Despite a dynamic and increasingly crowded therapeutic landscape, there are no reliable tools to predict which patients will benefit most from a given regimen. Disease heterogeneity, including etiology (hepatitis B, hepatitis C, metabolic) and tumor biology, is often underrepresented in stratification. Both emphasize the urgent need for biomarker-driven approaches to avoid unnecessary toxicity, optimize sequencing of therapy, and move toward a more precise oncology paradigm in HCC.

This segment reinforces that clinical judgment, patient engagement, and real-world practicality are central to optimizing dual checkpoint therapy, while also highlighting the broader research gaps that remain in personalized HCC management.